ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2366

The Clinical Utility of the Bulge Sign in Evaluating Knee Osteoarthritis

Fatimah Al Eid1, Timothy E. McAlindon2, Ming Zhang3 and Jeffrey Driban3, 1Rheumatology, Tufts Medical Center, Boston, MA, 2Division of Rheumatology, Tufts Medical Center, Boston, MA, 3Tufts Medical Center, Boston, MA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Evaluation, Knee, osteo-anabolics and test

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Osteoarthritis – Clinical Aspects - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Despite clinicians commonly using the bulge sign test to assess presence of knee effusion, prior studies have questioned the validity of the test to detect the prevalence of knee effusion based on ultrasound imaging. It remains unknown if the bulge sign test over time is a sensitive test to detect changes in knee effusion. Hence, we evaluated the association between the bulge sign test and magnetic resonance (MR) imaging-based knee effusion volume at a single visit and change over 2 years.

Methods: We selected individuals from the Osteoarthritis Initiative (OAI) who had no radiographic knee osteoarthritis at baseline and had MR images and a clinical exam at baseline and 24-month OAI visits. We enriched the sample to include 250 individuals who had an increase in radiographic severity (Kellgren-Lawrence grade). We selected the 1 knee per person. Two readers used a semi-automated software to quantify MR-based knee effusion volume (includes synovitis and effusion; intra-tester reliability: 0.73 to 0.97). Reader 1 reviewed all segmented images to ensure consistency between readers, knees, and time. The bulge sign was performed during a standardized clinical exam. We defined an incident bulge sign as a person with a positive bulge sign at the 24-month visit but not at baseline. We used an independent-sample t-test to compare baseline effusion volume between those with and without a positive bulge sign at baseline. A second independent-test was used to compare change in effusion volume between those with an incident bulge sign and those who never had a positive bulge sign. We also used logistic regression with ROC curves to explore the optimal cutpoint for baseline effusion volume and change in effusion volume for baseline positive bulge sign and incident bulge sign, respectively.

Results are reported as mean (standard deviation). Results: At baseline of OAI visit 352 participants were eligible participants with a mean age of 59.6 (8.6) years, mean BMI of 28.4 (4.5) kg/m2, and 62% female. The 47 participants with a positive bulge sign (15.38 [12.83] cm3) had greater knee effusion (t=-3.45, p=0.001) than those without a positive bulge sign (8.81 [6.14] cm3). Based on an ROC curve, knee effusion volume had an area under the curve of 0.67 with an optimal cutoff between those with and without a positive bulge sign of 8.39 cm3. At the 24-month OAI visit, the 40 (14%) participants with an incident positive bulge sign (9.85 [11.90] cm3) had greater increases in knee effusion volume(t = -4.21, p = 0.0001) than the 251 participants without an incident positive bulge sign (1.65 [7.69] cm3). Based on an ROC curve, change in knee effusion volume had an area under the curve of 0.70 with an optimal cutoff between those with and without a positive bulge sign of 2.06 cm3.

Conclusion:  The bulge sign test is associated with effusion volume and changes in effusion volume but may misclassify individuals with and without larger volumes of effusion or those with larger increases in knee effusion volume. Clinicians and researchers need to be aware of these properties when relying on the bulge sign test.


Disclosure: F. Al Eid, None; T. E. McAlindon, None; M. Zhang, None; J. Driban, None.

To cite this abstract in AMA style:

Al Eid F, McAlindon TE, Zhang M, Driban J. The Clinical Utility of the Bulge Sign in Evaluating Knee Osteoarthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-clinical-utility-of-the-bulge-sign-in-evaluating-knee-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-clinical-utility-of-the-bulge-sign-in-evaluating-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology